New Research from Dr. Glenn Isaacson and Lewis Katz School of Medicine Colleagues on Ibuprofen and Its Use in Children with G6PD Blood Cell Disorder

About 400 million people worldwide are deficient in glucose-6-phosphate dehydrogenase (G6PD), leaving blood cells vulnerable to oxidation and a destructive process known as hemolysis, which can result in severe, potentially life-threatening anemia. Certain foods and medications may precipitate the destruction of blood cells, especially in children. Ibuprofen is included on the list of suspected hemolysis-inducing drugs in G6PD-deficient children. However, a recent literature review by researchers at the Lewis Katz School of Medicine at Temple University suggests that ibuprofen should be removed from the list. Glenn Isaacson, MD, FACS, FAAP, Professor of Otolaryngology – Head and Neck Surgery and Pediatrics at the Katz School of Medicine and Director of Pediatric Otolaryngology at Temple University Hospital, is the senior investigator on the new study, which was published online in the journal The Laryngoscope. Dr. Isaacson was joined by Ashley N. Pankey, a fourth-year Katz School of Medicine student and lead author on the report, and Ashwin Chandar, MD, Assistant Professor of Medicine at the Katz School of Medicine. Medical Xpress highlighted the research.